Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOWTRL)

Drug Name

GSK-2315698 Drug Info

Synonyms

GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline

Indication

Disease Entry	ICD 11	Status	REF
Amyloidosis	5D00	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serum amyloid P-component (APCS)	TTB7VAT	SAMP_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Serum amyloid P-component (APCS)	DTT	APCS	12.393	5.113	5.459	5.182

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Amyloidosis

ICD Disease Classification

5D00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serum amyloid P-component (APCS)	DTT	APCS	3.02E-01	-0.06	-0.21

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
2	Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.